{"id":12955,"date":"2022-06-13T09:14:38","date_gmt":"2022-06-13T07:14:38","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=12955"},"modified":"2026-03-03T10:53:02","modified_gmt":"2026-03-03T09:53:02","slug":"eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/","title":{"rendered":"Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets serait dangereux et contre-productif"},"content":{"rendered":"\n<p><strong>Les deux derni\u00e8res ann\u00e9es pass\u00e9es ont montr\u00e9 une fois de plus toute l\u2019importance d\u2019efforts de recherche durables contre les mutations de virus et les futures pand\u00e9mies. Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets, comme il devrait \u00eatre discut\u00e9 lors de la douzi\u00e8me Conf\u00e9rence minist\u00e9rielle de l\u2019OMC, menacerait directement ces progr\u00e8s et ne ferait rien pour une distribution \u00e9quitable des vaccins. Dans la lutte contre une pand\u00e9mie, une protection solide de la propri\u00e9t\u00e9 intellectuelle n\u2019est pas une partie du probl\u00e8me, mais une partie de la solution.<\/strong><\/p>\n\n\n\n<p>L\u2019Organisation mondiale du commerce (OMC) va tenir \u00e0 Gen\u00e8ve dans les prochains jours une Conf\u00e9rence minist\u00e9rielle. Parmi les th\u00e8mes qui seront abord\u00e9s, on trouve une proposition \u00e9manant \u00e0 l\u2019origine de 4 membres (Afrique du Sud, \u00c9tats-Unis, Inde et Union europ\u00e9enne d\u00e9sign\u00e9s sous le nom de \u00ab&nbsp;Quad&nbsp;\u00bb) pour une d\u00e9rogation aux ADPIC<a href=\"#_ftn1\" id=\"_ftnref1\">[1]<\/a>. Cette proposition consiste en une s\u00e9rie de \u00ab\u00a0clarifications\u00a0\u00bb qui, prises ensemble, \u00e9largiraient la capacit\u00e9 des pays en d\u00e9veloppement \u00e0 \u00e9mettre des licences obligatoires de brevets li\u00e9s \u00e0 la production et \u00e0 la fourniture de vaccins COVID-19, au-del\u00e0 de ce qui est actuellement autoris\u00e9 par l&rsquo;Accord sur les ADPIC de l&rsquo;OMC.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-une-proposition-inacceptable\"><strong>Une proposition inacceptable<\/strong><\/h2>\n\n\n\n<p>Le texte propos\u00e9 par les 4 auteurs a \u00e9t\u00e9 formellement pr\u00e9sent\u00e9 \u00e0 tous les pays membres de l\u2019OMC le 6 mai. Cette proposition traite la propri\u00e9t\u00e9 intellectuelle comme un probl\u00e8me, alors qu\u2019elle est la solution.<\/p>\n\n\n\n<p>Ce texte va bien au-del\u00e0 des ADPIC<a href=\"#_ftn2\" id=\"_ftnref2\">[2]<\/a>. Il ne se limite \u00e9galement pas aux vaccins. Il inclut les brevets pour toutes les technologies et tous les processus n\u00e9cessaires \u00e0 la fabrication des vaccins (par exemple les r\u00e9actifs chimiques\/biologiques ou les \u00e9quipements et machines de production, etc.).<\/p>\n\n\n\n<p>Cette proposition a aussi le risque de devenir une nouvelle norme, bien au-del\u00e0 du contexte du COVID-19 auquel elle est cens\u00e9e \u00eatre destin\u00e9e, pour les futures pand\u00e9mies, mais aussi pour les situations non-pand\u00e9miques.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>La propri\u00e9t\u00e9 intellectuelle n\u2019est pas un obstacle \u00e0 la production et \u00e0 la vaccination<\/strong><\/h2>\n\n\n\n<p>Quelques chiffres&nbsp;:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>A ce jour, plus de 13 milliards de doses de vaccins anti-COVID ont \u00e9t\u00e9 produites<a href=\"#_ftn3\" id=\"_ftnref3\">[3]<\/a>&nbsp;:<\/li><li>A fin janvier, COVAX a livr\u00e9 son premier milliard de doses de vaccins et plus de 4 milliards de doses ont \u00e9t\u00e9 livr\u00e9es \u00e0 des pays \u00e0 revenu faible ou moyen inf\u00e9rieur&nbsp;;<\/li><li>Actuellement des stocks importants de vaccins, y compris dans les pays \u00e0 faible revenus, attendent d\u2019\u00eatre inocul\u00e9s.<\/li><\/ul>\n\n\n\n<p>Le probl\u00e8me actuel se situe au niveau des taux de vaccination des populations. Toute proposition visant \u00e0 affaiblir la propri\u00e9t\u00e9 intellectuelle ne permettrait en rien d\u2019am\u00e9liorer leurs niveaux.<\/p>\n\n\n\n<p>De telles propositions occultent, d\u2019une part, les efforts consid\u00e9rables qu\u2019ont d\u00e9ploy\u00e9 et que d\u00e9ploient encore (volontairement) les entreprises pharmaceutiques pour distribuer rapidement et \u00e9quitablement les vaccins et m\u00e9dicaments dans le monde entier:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>plusieurs groupes pharmaceutiques se sont engag\u00e9s \u00e0 proposer leurs vaccins sur une base non tourn\u00e9e vers le profit&nbsp;;<\/li><li>d\u2019autres ont diff\u00e9renci\u00e9 leurs prix en fonction des pays, de mani\u00e8re \u00e0 en permettre l\u2019acc\u00e8s \u00e0 des r\u00e9gions \u00e9conomiquement plus faibles&nbsp;;<\/li><li>en outre, les entreprises pharmaceutiques coop\u00e8rent avec des partenaires locaux et s\u2019engagent dans diverses initiatives et plateformes.<a href=\"#_ftn4\" id=\"_ftnref4\">[4]<\/a><\/li><\/ul>\n\n\n\n<p>D\u2019autre part, si les vaccins ont \u00e9t\u00e9 d\u00e9velopp\u00e9s en un temps record, c\u2019est aussi parce que les entreprises b\u00e9n\u00e9ficient de la s\u00e9curit\u00e9 juridique et des ressources qui vont de pair avec un syst\u00e8me solide de protection de leur propri\u00e9t\u00e9 intellectuelle. La protection conf\u00e9r\u00e9e par les brevets est la condition au transfert de connaissances vers des partenaires choisis pour \u00e9toffer les capacit\u00e9s de production. Ces partenariats ont fait leurs preuves. Vu le grand risque d\u2019\u00e9chec (comme on a pu l\u2019observer maintes fois ces derniers temps) et les investissements consid\u00e9rables que les entreprises doivent en m\u00eame temps consentir, miner la protection conf\u00e9r\u00e9e par les brevets cr\u00e9erait une ins\u00e9curit\u00e9 et mettrait en danger l\u2019avenir de telles activit\u00e9s de recherche, voire les rendrait impossibles.<\/p>\n\n\n\n<p>Des exceptions \u00e0 l\u2019accord ADPIC mineraient les incitations \u00e0 la recherche de nouveaux produits diagnostiques, vaccins et m\u00e9dicaments contre le COVID-19. Les deux ann\u00e9es que nous venons de vivre nous ont clairement montr\u00e9 que nous ne vaincrons pas de nouvelles pand\u00e9mies malgr\u00e9, mais au contraire, gr\u00e2ce \u00e0 une protection solide de la propri\u00e9t\u00e9 intellectuelle.<\/p>\n\n\n\n<p>Nous savons maintenant parfaitement que la fabrication de vaccins n\u2019est pas une simple question de production. La lutte contre de nouveaux variants, de nouveaux virus et de nouvelles menaces \u00e9mergentes implique des activit\u00e9s de recherche et d\u00e9veloppement continues qu\u2019une solide protection de la propri\u00e9t\u00e9 intellectuelle favorise en tout point.<\/p>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<p><a href=\"#_ftnref1\" id=\"_ftn1\">[1]<\/a> Accord international sur les aspects des droits de propri\u00e9t\u00e9 intellectuelle qui touchent au commerce<\/p>\n\n\n\n<p><a href=\"#_ftnref2\" id=\"_ftn2\">[2]<\/a> Accord de l&rsquo;OMC sur les aspects des droits de propri\u00e9t\u00e9 intellectuelle qui touchent au commerce<\/p>\n\n\n\n<p><a href=\"#_ftnref3\" id=\"_ftn3\">[3]<\/a> https:\/\/www.efpia.eu\/media\/637039\/efpia-vaccines-infographic-may-2022-1.pdf<\/p>\n\n\n\n<p><a href=\"#_ftnref4\" id=\"_ftn4\">[4]<\/a> https:\/\/www.ifpma.org\/resource-centre\/pharma-innovation-delivers-covid-19-solutions-beyond-expectations-but-calls-for-the-dilution-of-intellectual-property-rights-are-counteproductive<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les deux derni\u00e8res ann\u00e9es pass\u00e9es ont montr\u00e9 une fois de plus toute l\u2019importance d\u2019efforts de recherche durables contre les mutations de virus et les futures pand\u00e9mies. Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets, comme il devrait \u00eatre discut\u00e9 lors de la douzi\u00e8me Conf\u00e9rence minist\u00e9rielle de l\u2019OMC, menacerait directement ces progr\u00e8s et ne ferait [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":14161,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[118,113],"class_list":["post-12955","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-vaccin","tag-covid-19-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets serait dangereux et contre-productif - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets serait dangereux et contre-productif\" \/>\n<meta property=\"og:description\" content=\"Les deux derni\u00e8res ann\u00e9es pass\u00e9es ont montr\u00e9 une fois de plus toute l\u2019importance d\u2019efforts de recherche durables contre les mutations de virus et les futures pand\u00e9mies. Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets, comme il devrait \u00eatre discut\u00e9 lors de la douzi\u00e8me Conf\u00e9rence minist\u00e9rielle de l\u2019OMC, menacerait directement ces progr\u00e8s et ne ferait [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T07:14:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T09:53:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-066-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1097\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets serait dangereux et contre-productif\",\"datePublished\":\"2022-06-13T07:14:38+00:00\",\"dateModified\":\"2026-03-03T09:53:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/\"},\"wordCount\":873,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-066-scaled.jpg\",\"keywords\":[\"Vaccin\",\"Covid-19\"],\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/\",\"name\":\"Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets serait dangereux et contre-productif - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-066-scaled.jpg\",\"datePublished\":\"2022-06-13T07:14:38+00:00\",\"dateModified\":\"2026-03-03T09:53:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-066-scaled.jpg\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-066-scaled.jpg\",\"width\":2560,\"height\":1097,\"caption\":\"The concept of business, technology, the Internet and the network. A young entrepreneur working on a virtual screen of the future and sees the inscription: Intellectual property\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets serait dangereux et contre-productif\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets serait dangereux et contre-productif - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/","og_locale":"fr_FR","og_type":"article","og_title":"Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets serait dangereux et contre-productif","og_description":"Les deux derni\u00e8res ann\u00e9es pass\u00e9es ont montr\u00e9 une fois de plus toute l\u2019importance d\u2019efforts de recherche durables contre les mutations de virus et les futures pand\u00e9mies. Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets, comme il devrait \u00eatre discut\u00e9 lors de la douzi\u00e8me Conf\u00e9rence minist\u00e9rielle de l\u2019OMC, menacerait directement ces progr\u00e8s et ne ferait [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/","og_site_name":"Interpharma","article_published_time":"2022-06-13T07:14:38+00:00","article_modified_time":"2026-03-03T09:53:02+00:00","og_image":[{"width":2560,"height":1097,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-066-scaled.jpg","type":"image\/jpeg"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets serait dangereux et contre-productif","datePublished":"2022-06-13T07:14:38+00:00","dateModified":"2026-03-03T09:53:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/"},"wordCount":873,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-066-scaled.jpg","keywords":["Vaccin","Covid-19"],"inLanguage":"fr-FR","copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/","name":"Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets serait dangereux et contre-productif - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-066-scaled.jpg","datePublished":"2022-06-13T07:14:38+00:00","dateModified":"2026-03-03T09:53:02+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-066-scaled.jpg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-066-scaled.jpg","width":2560,"height":1097,"caption":"The concept of business, technology, the Internet and the network. A young entrepreneur working on a virtual screen of the future and sees the inscription: Intellectual property"},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/eine-schwaechung-des-patentschutzes-waere-gefaehrlich-und-kontraproduktiv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Un affaiblissement de la protection conf\u00e9r\u00e9e par les brevets serait dangereux et contre-productif"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=12955"}],"version-history":[{"count":1,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12955\/revisions"}],"predecessor-version":[{"id":12956,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12955\/revisions\/12956"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/14161"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=12955"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=12955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}